The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11111 malaria professionals are enjoying the free benefits of MalariaWorld today

transmission-blocking vaccine

Monoclonal antibodies block transmission of genetically diverse Plasmodium falciparum strains to mosquitoes

August 17, 2021 - 15:08 -- Open Access
Author(s): 
de Jong RM, Meerstein-Kessel L, Da DF, Nsango S, Challenger JD, van de Vegte-Bolmer M, van Gemert GJ, Duarte E, Teyssier N, Sauerwein RW, Churcher TS, Dabire RK, Morlais I, Locke E, Huynen MA, Bousema T, Jore MM
Reference: 
NPJ Vaccines. 2021 Aug 12;6(1):101

Malaria parasite transmission to mosquitoes relies on the uptake of sexual stage parasites during a blood meal and subsequent formation of oocysts on the mosquito midgut wall. Transmission-blocking vaccines (TBVs) and monoclonal antibodies (mAbs) target sexual stage antigens to interrupt human-to-mosquito transmission and may form important tools for malaria elimination.

Predicting the public health impact of a malaria transmission-blocking vaccine

March 10, 2021 - 13:16 -- Open Access
Author(s): 
Challenger JD, Olivera Mesa D, Da DF, Yerbanga RS, Lefèvre T, Cohuet A, Churcher TS
Reference: 
Nat Commun. 2021 Mar 8;12(1):1494

Transmission-blocking vaccines that interrupt malaria transmission from humans to mosquitoes are being tested in early clinical trials. The activity of such a vaccine is commonly evaluated using membrane-feeding assays. Understanding the field efficacy of such a vaccine requires knowledge of how heavily infected wild, naturally blood-fed mosquitoes are, as this indicates how difficult it will be to block transmission.

NOT Open Access | Design of Dissolvable Microneedles for Delivery of a Pfs47-Based Malaria Transmission-Blocking Vaccine

February 23, 2021 - 12:58 -- NOT Open Access
Author(s): 
Yenkoidiok-Douti L, Barillas-Mury C, Jewell CM
Reference: 
ACS Biomater Sci Eng. 2021 Feb 22

The development of effective malaria vaccines remains a global health priority. In addition to an effective vaccine, there is urgent demand for effective delivery technologies that can be easily deployed. The need for effective vaccine delivery tools is particularly pertinent in resource-poor settings where access to healthcare is limited. Microneedles are micron-scale structures that offer distinct advantages for vaccine delivery by efficiently targeting skin-resident immune cells, eliminating injection-associated pain, and improving patient compliance.

Subscribe to RSS - transmission-blocking vaccine